PET PHARM BIOTECH CO., LTD.
Update：2026/07/22
Industries
Main Industry
Biotechnology
Main Product/Service
1. Fluorodeoxyglucose injection(¹⁸F-FDG)
2. ¹⁸F-NaF
3. ¹⁸F-NaF
4. 131I capsule
2. ¹⁸F-NaF
3. ¹⁸F-NaF
4. 131I capsule
Founded Year
2011
Unified Business No.
53541504
Status
Active
Number of Employees
0
Total Paid-in
Capital
572,328,410 (NT$)
Location of Company
Taiwan
, New Taipei City
Exit Status
Emerging Stock Exchange(2025)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Since its establishment, Gison Biotech has been dedicated to the research, development, and production of radiopharmaceuticals, providing high-quality medical solutions to patients nationwide. We strive to be the best partner for nuclear medicine physicians and patients alike. Our vision is to advance precision treatment in nuclear medicine, improve patient health, and become a leader in the radiopharmaceutical field both in Taiwan and globally. With innovation, quality, and service at our core, we are committed to driving the future of radiopharmaceuticals forward.
